[{"id":"45d6876a-9de7-4fec-9066-9b91d75a0067","acronym":"LAL TEL/ALM1","url":"https://clinicaltrials.gov/study/NCT01282593","created_at":"2021-01-18T05:12:12.609Z","updated_at":"2024-07-02T16:35:47.231Z","phase":"","brief_title":"Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).","source_id_and_acronym":"NCT01282593 - LAL TEL/ALM1","lead_sponsor":"Rennes University Hospital","biomarkers":" CD9","pipe":" | ","alterations":" CD9 expression","tags":["CD9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD9 expression"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 10/11/2018","primary_completion_date":" 10/11/2018","study_txt":" Completion: 10/11/2018","study_completion_date":" 10/11/2018","last_update_posted":"2023-05-24"}]